A Solicitation of the National Institutes of Health (NIH) and The Centers for Disease Control and Prevention (CDC) for Small Business Innovation Research (SBIR) Contract Proposals

Predicted recompete opportunity based on federal award data.
Current Contract: 75N93023C00039 Incumbent: SILVER LAKE RESEARCH CORPORATION Contract Value: $750,000 Potential End Date: 2026-08-31T00:00:00.000Z Competition: FULL AND OPEN COMPETITION AFTER EXCLUSION OF SOURCES Pricing: FIRM FIXED PRICE Classification: full-recompete (Confidence: high - 90/100)
The National Institutes of Health (NIH) and the Centers for Disease Control and Prevention (CDC) are soliciting proposals from small business concerns that possess the research and development (R&D) expertise to conduct innovative research that will contribute toward NIH or CDC mission needs and Small Business Innovation Research (SBIR) program objectives. THE U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES (DHHS), THE NATIONAL INSTITUTES OF HEALTH (NIH), AND THE CENTERS FOR DISEASE CONTROL AND PREVENTION (CDC) SMALL BUSINESS INNOVATIVE RESEARCH (SBIR) PROGRAM SOLICITATION PHS-2023-1 is anticipated to be made available on or around August 4, 2022, through both SAM.gov and the NIH Small Business Innovation Research (SBIR)/Small Business Technology Transfer (STTR) funding web page at https://sbir.nih.gov/funding. This solicitation is anticipated to have a closing date of November 4, 2022 for receipt of proposals. The purposes of the SBIR program are to: (a) stimulate technological innovation; (b) strengthen the role of small business in meeting Federal research/research & development (R/R&D) needs; (c) foster and encourage participation by socially and economically disadvantaged small business concerns and women-owned business concerns; and (d) increase private sector commercialization of innovations derived from Federal R/R&D, thereby increasing competition, productivity and economic growth. For purposes of the SBIR program, a small business concern is any business concern that, on the date of award, (1) is organized for profit, with a place of business located in the United States, which operates primarily within the United States or which makes a significant contribution to the United States economy through payment of taxes or use of American products, materials or labor; (2) is in the legal form of an individual proprietorship, partnership, limited liability company, corporation, joint venture, association, trust or cooperative, except that where the form is a joint venture, there must be less than 50 percent participation by foreign business entities in the joint venture; (3) more than 50% directly owned and controlled by one or more individuals (who are citizens or permanent resident aliens of the United States), other business concerns (each of which is more than 50% directly owned and controlled by individuals who are citizens or permanent resident aliens of the United States), or any combination of these; OR more than 50% owned by multiple venture capital operating companies, hedge funds, private equity firms, or any combination of these. No single venture capital operating company, hedge fund, or private equity firm may own more than 50% of the concern; AND, (4) has, including its affiliates, no more than 500 employees.* * Note: This size standard is established by law for the SBIR program, regardless of the NAICS Code assigned. See 13 C.F.R. - 121.702. THE FOLLOWING RESEARCH TOPICS ARE ANTICIPATED TO BE INCLUDED IN SBIR CONTRACT SOLICITATION PHS-2023-1 NATIONAL INSTITUTES OF HEALTH (NIH) NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES (NCATS): Topic 023 - Development of Automated Cell Culture Flask Cleaning Instrument NATIONAL CANCER INSTITUTE (NCI): Topic 446 - Development of Senotherapeutic Agents for Cancer Treatment Topic 447 - Non-invasive Device Technology Research & Development for Chemotherapy-induced Peripheral Neuropathy Management Topic 448 - Wearable Devices for Dosimetry of Radiopharmaceutical Therapy Topic 449 - Wearable Technologies to Facilitate Remote Monitoring of Cancer Patients Following Treatment Topic 450 - Technology Platforms for Circulating Tumor-Macrophage Hybrid Cells Topic 451 - Rapid and Affordable Point-of-Care HPV Diagnostics for Cervical Cancer Control Topic 452 - Translation of Novel Cancer-Specific Imaging Agents and Techniques to Mediate Successful Image-Guided Cancer Interventions Topic 453 - Digital Tools to Integrate Cancer Prevention Within Primary Care Topic 454 - Software to Evaluate Artificial Intelligence/Machine Learning Medical Devices in Oncology Settings NATIONAL INSTITUTE ON AGING (NIA): Topic 007 - High Throughput CHIP (clonal hematopoeisis of indeterminate potential) Assay as a Powerful Tool to Study CHIP Related Age Associated Diseases Topic 008 - Improving Microphysiological Systems for AD/ADRD Therapy Development Topic 009 - AI/ML Tool for Visualizing Behavioral and Social Science Research NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES (NIAID): Topic 113 - Development of a Simian Immunodeficiency Virus (SIV) and Simian Human Immunodeficiency Virus (SHIV) Database Topic 114 - Point-of-Care HIV Viral Load, Drug Resistance, and Adherence Assays Topic 115 - Development of Diagnostics to Differentiate HIV Infection from Vaccine-Induced Seropositivity Topic 116 - Adjuvant Discovery for Vaccines for Infectious and Immune-Mediated Diseases Topic 117 - Adjuvant Development for Vaccines for Infectious and Immune-Mediated Diseases Topic 118 - Reagents for Immunologic Analysis of Non-mammalian and Underrepresented Mammalian Models Topic 119 - Adaptation of CRISPR-based in vitro Diagnostics for Rapid Detection of Select Eukaryotic Pathogens Topic 120 - Modular Sample Preparation for In-Field Viral Discovery Topic 121 - Artificial Intelligence to Improve Clinical Microscopy for Diagnosis of Infectious Diseases Topic 122 - Advanced and Immersive Visualization Tools for Infectious and Immune-mediated Disease Research Topic 123 - Data Science Tools for Infectious and Immune-mediated Disease Research NATIONAL HEART, LUNG, AND BLOOD INSTITUTE (NHLBI): Topic 113 - Clinical Instrument for Para-Hydrogen (pH2) Based Signal Amplification by Reversible Exchange (SABRE) for Hyperpolarizing 13C-Pyruvate and Other Probes for MRI Imaging Topic 114 - Device to Permit Continuous Self-Monitoring of Blood Oxygen Saturation During Activities of Daily Living for Individuals at Risk for Desaturation During Physical Exertion NATIONAL INSTITUTE ON DRUG ABUSE (NIDA): Topic 167 - Cause of Death Elucidated (CODE) in Drug Overdose: Research and Development of New Postmortem Toxicology Screening Devices that are Portable, Rapid, Accurate, Affordable, and Accessible CENTERS FOR DISEASE CONTROL AND PREVENTION (CDC) NATIONAL CENTER FOR EMERGING ZOONOTIC AND INFECTIOUS DISEASE (NCEZID): Topic 030 - Developing an Over-the-Counter Diagnostic Test for Valley Fever NATIONAL CENTER FOR HIV/AIDS, VIRAL HEPATITIS, STD, AND TB PREVENTION (NCHHSTP): Topic 054 - School Illness-Related Absenteeism and Learning Modality Surveillance NOTE - SBIR / STTR GRANT OPPORTUNITIES SBIR and STTR grant opportunities are also available for investigator-initiated ideas. Companies are encouraged to review omnibus SBIR/STTR grant solicitations of the National Institutes of Health, Centers for Disease Control and Prevention and Food and Drug Administration posted on the NIH SBIR/STTR funding web page located at https://sbir.nih.gov/funding#omni-sbir. Standard due dates for SBIR/STTR grant applications are September 5th, January 5th, and April 5th. To understand better the differences between grants and contracts, see https://sbir.nih.gov/apply. For general information regarding the NIH/CDC SBIR Program, please refer to: Office of Extramural Programs, Office of Extramural Research National Institutes of Health Phone +1 (555) 000-0000 contact@example.gov